|
Apr 24
|
ORYZON Raises €30 Million in Capital Increase
|
|
Apr 21
|
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
|
|
Apr 15
|
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
|